Sequent Scientific Limited , a prominent player in the pharmaceuticals sector, has taken another significant step to enhance employee engagement and ownership. The company's Nomination and Remuneration Committee has approved the allotment of 11,63,301 equity shares under its Employee Stock Option Plan 2020 (SeQuent ESOP 2020).

Latest Allotment Details

The committee approved the latest share allotment through a resolution passed by circulation, demonstrating the company's commitment to swift decision-making while adhering to corporate governance norms.

Updated Share Capital Structure

The allotment has resulted in a further increase in the company's paid-up equity share capital, building upon previous ESOP allotments:

Strategic Significance

This equity share allotment under the ESOP scheme continues to serve multiple strategic purposes for Sequent Scientific:

Employee Retention and Motivation: By offering stock options, the company aims to retain key talent and align employee interests with long-term organizational goals. The ESOP acts as a powerful incentive for employees to contribute to the company's growth and success.

Wealth Creation Opportunity: The scheme provides employees with an opportunity to benefit from the company's potential future growth and share price appreciation, fostering a culture of ownership.

Equity Rights and Compliance

The newly allotted shares will rank pari-passu with the existing equity shares of the company, ensuring equal rights in terms of voting and dividends as previously issued shares. This maintains equity among all shareholders while expanding the employee ownership base.

Market Position

As a mid-cap company in the pharmaceuticals sector with a market capitalization of ₹5,467.50 crores, Sequent Scientific continues to strengthen its position through strategic employee engagement initiatives. The company's focus on fostering shared success among its workforce reflects its commitment to sustainable growth in the competitive life sciences market.

Sequent Scientific Limited has announced significant developments in its ongoing composite scheme of amalgamation. The company has informed the stock exchanges about two important record dates and share exchange ratios related to different aspects of the merger process.

Viyash Life Sciences and Sequent Scientific Merger

Sequent Scientific has set December 08, 2025, as the record date to determine shareholders of Viyash Life Sciences for allotment of merger consideration shares following NCLT approval of the composite amalgamation scheme. The share exchange ratio for this merger has been fixed as follows:

Viyash Life Sciences and Geninn Life Sciences Merger

In a separate but related development, Viyash Life Sciences Private Limited has set November 1, 2025, as the Record Date for determining the shareholders of Geninn Life Sciences Private Limited who will be eligible for share allotment as part of their merger process.

Composite Scheme of Amalgamation

These announcements are part of a larger composite scheme of amalgamation involving several entities, including:

• Sequent Scientific Limited
• Symed Labs Limited
• Vandana Life Sciences Private Limited
• Appcure Labs Private Limited
• Vindhya Pharma (India) Private Limited
• S.V. Labs Private Limited
• Vindhya Organics Private Limited
• Viyash Life Sciences Private Limited
• Geninn Life Sciences Private Limited
• Sequent Research Limited

Implications for Shareholders

The record dates and share exchange ratios are crucial elements in the merger process, providing clarity to the shareholders of the involved companies about their entitlement in the merged entities. These corporate actions represent significant steps in the ongoing restructuring and consolidation within the Sequent Scientific group of companies.

Investors and stakeholders of Sequent Scientific should take note of these developments as they may have implications for the company's structure and operations moving forward.